Financials data is unavailable for this security.
View more
Year on year Plus Therapeutics Inc 's revenues fell -27.85% from 14.73m to 10.63m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 23.22m to a larger loss of 27.49m.
Gross margin | -- |
---|---|
Net profit margin | -240.15% |
Operating margin | -256.07% |
Return on assets | -104.14% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
SmartText is unavailable
Cash flow per share | -2.72 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -1.34 |
---|---|
Tangible book value per share | -1.50 |
More ▼
Balance sheet in USDView more
SmartText is unavailable
Current ratio | 0.4993 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼